Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

From early adversities to immune activation in psychiatric disorders: the role of the sympathetic nervous system.

Mondelli V, Vernon AC.

Clin Exp Immunol. 2019 Sep;197(3):319-328. doi: 10.1111/cei.13351. Review.

PMID:
31319436
2.

The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells.

Duarte RRR, Bachtel ND, Côtel MC, Lee SH, Selvackadunco S, Watson IA, Hovsepian GA, Troakes C, Breen GD, Nixon DF, Murray RM, Bray NJ, Eleftherianos I, Vernon AC, Powell TR, Srivastava DP.

Biol Psychiatry. 2019 Jul 15;86(2):120-130. doi: 10.1016/j.biopsych.2019.03.977. Epub 2019 Mar 30.

3.

Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory.

Doostdar N, Kim E, Grayson B, Harte MK, Neill JC, Vernon AC.

J Psychopharmacol. 2019 Oct;33(10):1274-1287. doi: 10.1177/0269881119844196. Epub 2019 May 7.

PMID:
31060435
4.

Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects.

Murray KN, Edye ME, Manca M, Vernon AC, Oladipo JM, Fasolino V, Harte MK, Mason V, Grayson B, McHugh PC, Knuesel I, Prinssen EP, Hager R, Neill JC.

Brain Behav Immun. 2019 Jan;75:48-59. doi: 10.1016/j.bbi.2018.09.005. Epub 2018 Sep 12.

PMID:
30218784
5.

Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.

Calevro A, Cotel MC, Natesan S, Modo M, Vernon AC, Mondelli V.

Psychoneuroendocrinology. 2018 Sep;95:28-33. doi: 10.1016/j.psyneuen.2018.05.021. Epub 2018 May 16.

PMID:
29793094
6.

An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.

Hawkins PCT, Wood TC, Vernon AC, Bertolino A, Sambataro F, Dukart J, Merlo-Pich E, Risterucci C, Silber-Baumann H, Walsh E, Mazibuko N, Zelaya FO, Mehta MA.

Hum Brain Mapp. 2018 Jan;39(1):319-331. doi: 10.1002/hbm.23844. Epub 2017 Oct 23.

PMID:
29058358
7.

Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.

Amato D, Vernon AC, Papaleo F.

Neurosci Biobehav Rev. 2018 Feb;85:146-159. doi: 10.1016/j.neubiorev.2017.09.027. Epub 2017 Sep 29. Review.

PMID:
28970021
8.

Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.

Modo M, Crum WR, Gerwig M, Vernon AC, Patel P, Jackson MJ, Rose S, Jenner P, Iravani MM.

PLoS One. 2017 Jul 24;12(7):e0180733. doi: 10.1371/journal.pone.0180733. eCollection 2017.

9.

Brain microglia in psychiatric disorders.

Mondelli V, Vernon AC, Turkheimer F, Dazzan P, Pariante CM.

Lancet Psychiatry. 2017 Jul;4(7):563-572. doi: 10.1016/S2215-0366(17)30101-3. Epub 2017 Apr 25. Review.

PMID:
28454915
10.

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease.

Westphal R, Simmons C, Mesquita MB, Wood TC, Williams SC, Vernon AC, Cash D.

PLoS One. 2017 Mar 1;12(3):e0172394. doi: 10.1371/journal.pone.0172394. eCollection 2017.

11.

Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.

Notter T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, Wang Y, Kassiou M, Vernon AC, Benke D, Pomper MG, Sawa A, Meyer U.

Mol Psychiatry. 2018 Feb;23(2):323-334. doi: 10.1038/mp.2016.248. Epub 2017 Jan 17.

PMID:
28093569
12.

Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study.

Crum WR, Sawiak SJ, Chege W, Cooper JD, Williams SCR, Vernon AC.

Brain Behav Immun. 2017 Jul;63:50-59. doi: 10.1016/j.bbi.2016.12.008. Epub 2016 Dec 9.

13.

Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model.

Wood TC, Simmons C, Hurley SA, Vernon AC, Torres J, Dell'Acqua F, Williams SC, Cash D.

PeerJ. 2016 Nov 1;4:e2632. eCollection 2016.

14.

Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss.

Crum WR, Danckaers F, Huysmans T, Cotel MC, Natesan S, Modo MM, Sijbers J, Williams SC, Kapur S, Vernon AC.

Psychol Med. 2016 Nov;46(15):3081-3093. Epub 2016 Aug 12.

15.

Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.

Westphal R, Sumiyoshi A, Simmons C, Mesquita M, Wood TC, Williams SC, Vernon AC, Cash D.

Neuroscience. 2016 Oct 15;334:166-179. doi: 10.1016/j.neuroscience.2016.07.046. Epub 2016 Aug 6.

PMID:
27506141
16.

Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies.

Amato D, Beasley CL, Hahn MK, Vernon AC.

Neurosci Biobehav Rev. 2017 May;76(Pt B):317-335. doi: 10.1016/j.neubiorev.2016.10.004. Epub 2016 Oct 15. Review.

17.

Simultaneous effects on parvalbumin-positive interneuron and dopaminergic system development in a transgenic rat model for sporadic schizophrenia.

Hamburg H, Trossbach SV, Bader V, Chwiesko C, Kipar A, Sauvage M, Crum WR, Vernon AC, Bidmon HJ, Korth C.

Sci Rep. 2016 Oct 10;6:34946. doi: 10.1038/srep34946.

18.

Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic-polycytidylic acid in utero.

Vernon AC, So PW, Lythgoe DJ, Chege W, Cooper JD, Williams SC, Kapur S.

Eur Neuropsychopharmacol. 2015 Dec;25(12):2210-20. doi: 10.1016/j.euroneuro.2015.09.022. Epub 2015 Oct 21.

PMID:
26475576
19.

Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses.

Cotel MC, Lenartowicz EM, Natesan S, Modo MM, Cooper JD, Williams SC, Kapur S, Vernon AC.

Eur Neuropsychopharmacol. 2015 Nov;25(11):2098-107. doi: 10.1016/j.euroneuro.2015.08.004. Epub 2015 Aug 17.

PMID:
26321204
20.
21.

The brain's code and its canonical computational motifs. From sensory cortex to the default mode network: A multi-scale model of brain function in health and disease.

Turkheimer FE, Leech R, Expert P, Lord LD, Vernon AC.

Neurosci Biobehav Rev. 2015 Aug;55:211-22. doi: 10.1016/j.neubiorev.2015.04.014. Epub 2015 May 5. Review.

PMID:
25956253
22.

Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.

Finlay CJ, Duty S, Vernon AC.

Front Neurol. 2014 Jun 12;5:95. doi: 10.3389/fneur.2014.00095. eCollection 2014. Review.

23.

Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology.

Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, Cooper JD, Williams SC, Kapur S.

Biol Psychiatry. 2014 Jun 15;75(12):982-90. doi: 10.1016/j.biopsych.2013.09.012. Epub 2013 Oct 19.

PMID:
24143881
24.

Effects of lithium on magnetic resonance imaging signal might not preclude increases in brain volume after chronic lithium treatment.

Vernon AC, Hajek T.

Biol Psychiatry. 2013 Dec 15;74(12):e39-40. doi: 10.1016/j.biopsych.2012.12.028. Epub 2013 Aug 30. No abstract available.

PMID:
23998561
25.

Registration of challenging pre-clinical brain images.

Crum WR, Modo M, Vernon AC, Barker GJ, Williams SC.

J Neurosci Methods. 2013 May 30;216(1):62-77. doi: 10.1016/j.jneumeth.2013.03.015. Epub 2013 Apr 1.

26.

Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.

Mondelli V, Anacker C, Vernon AC, Cattaneo A, Natesan S, Modo M, Dazzan P, Kapur S, Pariante CM.

Transl Psychiatry. 2013 Jan 15;3:e208. doi: 10.1038/tp.2012.138.

27.

Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation.

Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SC, Kapur S.

Biol Psychiatry. 2012 May 15;71(10):855-63. doi: 10.1016/j.biopsych.2011.12.004. Epub 2012 Jan 15.

PMID:
22244831
28.

Do levodopa treatments modify the morphology of the parkinsonian brain?

Vernon AC, Modo M.

Mov Disord. 2012 Jan;27(1):166-7. doi: 10.1002/mds.24018. Epub 2011 Nov 10. No abstract available.

PMID:
22076912
29.

Selective activation of metabotropic glutamate receptor 7 induces inhibition of cellular proliferation and promotes astrocyte differentiation of ventral mesencephalon human neural stem/progenitor cells.

Vernon AC, Smith EJ, Stevanato L, Modo M.

Neurochem Int. 2011 Sep;59(3):421-31. doi: 10.1016/j.neuint.2011.04.001. Epub 2011 May 23.

PMID:
21624409
30.

Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.

Vernon AC, Crum WR, Johansson SM, Modo M.

PLoS One. 2011 Feb 25;6(2):e17269. doi: 10.1371/journal.pone.0017269.

31.

Non-invasive MR imaging of neurodegeneration in a rodent model of Parkinson's disease.

Vernon AC, Modo M.

Methods Mol Biol. 2011;711:487-510. doi: 10.1007/978-1-61737-992-5_25.

PMID:
21279619
32.

Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation.

Vernon AC, Natesan S, Modo M, Kapur S.

Biol Psychiatry. 2011 May 15;69(10):936-44. doi: 10.1016/j.biopsych.2010.11.010. Epub 2010 Dec 31.

PMID:
21195390
33.

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease.

Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, Dexter DT.

Parkinsons Dis. 2010 May 23;2010. pii: 190450. doi: 10.4061/2010/190450.

34.

Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?

Vernon AC, Ballard C, Modo M.

Brain Res Rev. 2010 Oct 5;65(1):28-55. doi: 10.1016/j.brainresrev.2010.05.006. Epub 2010 Jun 2. Review.

PMID:
20685363
35.

Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Vernon AC, Johansson SM, Modo MM.

BMC Neurosci. 2010 Jan 5;11:1. doi: 10.1186/1471-2202-11-1.

36.

Mice with reduced vesicular monoamine storage content display nonmotor features of Parkinson's disease.

Vernon AC.

J Neurosci. 2009 Oct 14;29(41):12842-4. doi: 10.1523/JNEUROSCI.4156-09.2009. No abstract available.

37.

Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.

Vernon AC, Croucher MJ, Dexter DT.

Neuroreport. 2008 Mar 5;19(4):475-8. doi: 10.1097/WNR.0b013e3282f602df.

PMID:
18287950
38.
39.

Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.

Vernon AC, Zbarsky V, Datla KP, Dexter DT, Croucher MJ.

J Pharmacol Exp Ther. 2007 Jan;320(1):397-409. Epub 2006 Sep 29.

PMID:
17012606
40.

Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.

Vernon AC, Palmer S, Datla KP, Zbarsky V, Croucher MJ, Dexter DT.

Eur J Neurosci. 2005 Oct;22(7):1799-806.

PMID:
16197521

Supplemental Content

Loading ...
Support Center